Human papillomavirus (HPV) is known to be associated with many types of cancers disproportionately affecting women. The most common of these is cervical cancer. However anal, vulvar, vaginal, penile, and oropharyngeal cancers have also been linked to this virus. It is estimated that 527 624 women receive a cervical cancer diagnosis annually and 265 653 die from the disease making it the third most common cancer among women globally (1). Anal cancer, while not as prevalent as cervical cancer, is on the rise with approximately 27 000 new cases identified worldwide each year. Women are at higher risk than men for anal cancer, especially those with cervical or vulvar cancers and those who are immunocompromised. Other conditions such as recurrent juvenile respiratory papillomatosis and genital warts are often attributed to HPV types 6 and 11.